Compound interest: the eighth wonder of the world
Setting up a pharmaceuticals trust in the mid-1990s taught Max King the power of compounding
Investors are regularly reminded that compound returns are the eighth wonder of the world. But you don’t understand quite what that means until you are on the receiving end of them. I only fully appreciated the truth of the saying after investing in Finsbury Worldwide Pharmaceutical Trust, now the Worldwide Healthcare Trust, from its inception in early 1995.
I was the lead fund manager at Finsbury Asset Management, which I had joined in 1987 with the objective of turning four small investment trusts into successful UK-focused funds suitable for retail investors.
Venturing abroad
By 1994, that process was well underway and our thoughts turned to launching a new trust. It is easy to forget how domestically-orientated most investors, even professional ones, were in those days, though with the FTSE 100 index producing compound capital returns, on trend, of 10% per annum, investing internationally wasn’t the necessity it now is.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
International funds were divided on geographic lines, which meant there was little comparison between companies in the same sector operating in the same global marketplace but listed on different national exchanges.
The sector that was most obviously crying out for an international approach was pharmaceuticals. The FTSE 100 contained four pharma stocks – Glaxo, SmithKlineBeecham, Wellcome and Zeneca – and there were also several smaller firms.
However, the largest stock, Glaxo, only ranked number five in the world, even though it had grown its sales at a compound rate of 20% for ten years. Given the long-term growth potential of the healthcare sector, as obvious then as it is now, there was a compelling case for a global fund able to cross national boundaries but with access to specialist scientific knowledge.
Fortunately, my colleagues, William Salomon and Tony Townsend, knew just where to go. Mehta and Isaly was a New York-based brokerage firm specialising in pharmaceuticals. It covered over 300 companies, had successfully managed a US fund for five years and was enthusiastic about a sector that, following the failure of the Clinton healthcare reforms, was valued at a historically low level. It agreed to partner with us in the launch of a new investment trust.
The launch was not a success, raising just £14m. About £10m of that came, as promised in advance, from Equitable Life, while a couple of other investors put up seven figure amounts. Among the smaller investors was our internal pension fund, including 10,000 shares at £1 each from me.
Despite their misgivings, the Stock Exchange permitted the listing to proceed. Since Sam Isaly was not authorised in the UK, he could only be an investment adviser. So, for the first two years, I was the official fund manager, a task that involved placing the orders which he “advised”. He was rather put out when I asked the reasons for his instructions but understood when I explained that I might be accountable for them and wanted to be able to field questions from investors without bothering him.
Small beginnings
The trust returned around 40% in the first year, on the back of which we managed to raise another £40m. Many investors saw a London-listed trust with an overwhelmingly international portfolio as a way to cheat on the UK constraint they were under. Since then, the number of shares in issue has grown moderately but the share price multiplied again and again.
Finsbury Asset Management was sold and I left, but rather than sell or cut my holding, I added to it. The most I paid was £5. Mehta and Isaly broke up; Isaly formed OrbiMed, a healthcare investment group, and it became the formal manager. The remit was broadened and the trust renamed. A few years ago, Isaly stepped back from OrbiMed but the trust has continued to prosper. Today’s share price close to £35 represents a compound return, excluding dividends, of 15% per annum.
What are the lessons from this story? Small beginnings don’t preclude big successes. Trusts needn’t be prolific share issuers to grow big. Long-term continuity of management and style is vital. And if you find an area offering secure long-term growth with expert management, stick to it like glue. As Warren Buffett advised, “lethargy bordering on sloth should remain the cornerstone of an investment style”.
Sign up to Money Morning
Our team, led by award winning editors, is dedicated to delivering you the top news, analysis, and guides to help you manage your money, grow your investments and build wealth.
Max has an Economics degree from the University of Cambridge and is a chartered accountant. He worked at Investec Asset Management for 12 years, managing multi-asset funds investing in internally and externally managed funds, including investment trusts. This included a fund of investment trusts which grew to £120m+. Max has managed ten investment trusts (winning many awards) and sat on the boards of three trusts – two directorships are still active.
After 39 years in financial services, including 30 as a professional fund manager, Max took semi-retirement in 2017. Max has been a MoneyWeek columnist since 2016 writing about investment funds and more generally on markets online, plus occasional opinion pieces. He also writes for the Investment Trust Handbook each year and has contributed to The Daily Telegraph and other publications. See here for details of current investments held by Max.
-
Investors pull money from UK equities as government warns of “painful” Budget
The government’s post-election honeymoon period has been short-lived, and investors are shying away from UK equities as a result
By Katie Williams Published
-
Top global fintech companies to invest in
One British fintech hogs the headlines, but there are two top performers in the US. We explain where you should put your money
By David C. Stevenson Published
-
Halifax: House price slump continues as prices slide for the sixth consecutive month
UK house prices fell again in September as buyers returned, but the slowdown was not as fast as anticipated, latest Halifax data shows. Where are house prices falling the most?
By Kalpana Fitzpatrick Published
-
Rents hit a record high - but is the opportunity for buy-to-let investors still strong?
UK rent prices have hit a record high with the average hitting over £1,200 a month says Rightmove. Are there still opportunities in buy-to-let?
By Marc Shoffman Published
-
Pension savers turn to gold investments
Investors are racing to buy gold to protect their pensions from a stock market correction and high inflation, experts say
By Ruth Emery Published
-
Where to find the best returns from student accommodation
Student accommodation can be a lucrative investment if you know where to look.
By Marc Shoffman Published
-
Best investing apps
We round up the best investing apps. Looking for an easy-to-use app to help you start investing, keep track of your portfolio or make trades on the go?
By Ruth Emery Last updated
-
The world’s best bargain stocks
Searching for bargain stocks with Alec Cutler of the Orbis Global Balanced Fund, who tells Andrew Van Sickle which sectors are being overlooked.
By Andrew Van Sickle Published
-
Revealed: the cheapest cities to own a home in Britain
New research reveals the cheapest cities to own a home, taking account of mortgage payments, utility bills and council tax
By Ruth Emery Published
-
UK recession: How to protect your portfolio
As the UK recession is confirmed, we look at ways to protect your wealth.
By Henry Sandercock Last updated